CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop new hybrid ruthenium-based chemotherapy drugs that can be activated by low-energy light. These innovative compounds are designed to target cancer cells more specifically, potentially reducing the side effects associated with traditional chemotherapy treatments.
The discovery of cisplatin, cis-diamminedichloroplatinum(II), as an anticancer drug is a landmark of modern inorganic medicinal chemistry.
Platinum drugs are the best-selling antitumor drugs in the world and they are effective in treating a variety of cancers.
During the last decade, the search for new anticancer compounds has been widened to other transition metals.
Ruthenium complexes in particular have shown considerable promise because of their rich synthetic chemistry, the range of oxidatio…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
